FOXA1 in prostate cancer

FOXA1 in prostate cancer

Most prostate cancers initially respond to androgen deprivation therapy (ADT). With the long-term application of ADT, localized prostate cancer will progress to castration-resistant prostate cancer (CRPC), metastatic CRPC (mCRPC), and neuroendocrine prostate cancer (NEPC), and the transcriptional ne...

Full description

Bibliographic Details
Main Authors: Hui-Yu Dong, Lei Ding, Tian-Ren Zhou, Tao Yan, Jie Li, Chao Liang
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Asian Journal of Andrology
Subjects:
androgen receptor; forkhead box protein a1; mutation; prostate cancer
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2023;volume=25;issue=3;spage=287;epage=295;aulast=Dong

Internet

http://www.ajandrology.com/article.asp?issn=1008-682X;year=2023;volume=25;issue=3;spage=287;epage=295;aulast=Dong

Similar Items